<p>Surmodics, Inc.（纳斯达克代码：SRDX - 获取免费报告）周一股价上涨了 8.7%，因其发布的财报超出预期。该公司股价最高达到 38.33 美元，最后交易价为 38.48 美元。在交易过程中，共成交 194,800 股，较 176,503 股的平均交易量增加了 10%。该股票此前收盘价为 35.41 美元。</p>
<p>该公司报告本季度每股收益为 0.06 美元，超出市场共识预期的-0.21 美元，超出幅度为 0.27 美元。Surmodics 的净利润率为-14.59%，股本回报率为-3.04%。该公司本季度的收入为 2957 万美元，而市场共识预期为 2804 万美元。</p>
<h2>分析师评级变动</h2>
<p>多家研究机构最近对 SRDX 发布了报告。Needham &amp; Company LLC 在 4 月 30 日的报告中重申了对 Surmodics 股票的 “持有” 评级。Barrington Research 在周一的报告中重申了对 Surmodics 股票的 “市场表现” 评级。</p>
<p><strong>获取我们关于 SRDX 的最新报告</strong></p>
<h2>机构资金流入和流出</h2>
<p>多家机构投资者和对冲基金最近对 SRDX 的持仓进行了调整。Strs Ohio 在第一季度购买了 Surmodics 的新股份，价值 12.2 万美元。Legal &amp; General Group Plc 在第四季度将其在 Surmodics 的持股增加了 34.2%。Legal &amp; General Group Plc 目前拥有 3452 股该公司的股票，价值 13.7 万美元，此前在上个季度又购买了 880 股。Price T Rowe Associates Inc. MD 在第四季度购买了 Surmodics 的新股份，价值 21.7 万美元。AlphaQuest LLC 在第一季度购买了 Surmodics 的新股份，价值 23.2 万美元。最后，DeepCurrents Investment Group LLC 在第四季度购买了 Surmodics 的新股份，价值 26 万美元。对冲基金和其他机构投资者持有该公司 96.63% 的股份。</p>
<h2>Surmodics 股价上涨 8.2%</h2>
<p>该公司的市值为 5.4778 亿美元，市盈率为-31.04，贝塔值为 1.31。该公司的速动比率为 3.10，流动比率为 3.91，债务与股本比率为 0.27。该公司的 50 日移动平均线为 31.27 美元，200 日移动平均线为 30.78 美元。</p>
<h2>关于 Surmodics</h2>
<p>（获取免费报告）</p>
<p>Surmodics, Inc 及其子公司在美国及国际上提供用于血管内医疗设备的性能涂层技术，以及用于体外诊断免疫测定测试和微阵列的化学和生物成分。它通过医疗设备和体外诊断（IVD）两个部门运营。</p>
<h2>阅读更多</h2>
<ul>
<li>我们更看好的五只股票比 Surmodics 更好</li>
<li>在 52 周高点盈利交易股票</li>
<li>甲骨文 2025 年的反弹仅完成一半：五个原因</li>
<li>为什么特别股息对收入投资者来说可能是一个愉快的惊喜</li>
<li>通过这五只 ETF 投资人工智能和能源基础设施</li>
<li>上升趋势股票解析：学习如何利用上升趋势进行交易</li>
<li>三只推动人工智能数据中心繁荣的天然气股票</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Surmodics 吗？</h2>
<p>在考虑 Surmodics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄推荐给客户的股票，以便在更广泛的市场注意到之前购买……而 Surmodics 并不在名单上。</p>
<p>虽然 Surmodics 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

SRDX

<p>Surmodics（纳斯达克代码：SRDX）股价上涨 8.7%，交易价格为 38.48 美元，此次上涨是由于其财报表现好于预期。公司每股收益为 0.06 美元，超出预期的-0.21 美元，营收为 2957 万美元。机构投资者持有该股票的 96.63%。尽管财报表现积极，分析师仍对该股票维持 “持有” 评级。Surmodics 专注于医疗设备和诊断测试的性能涂层技术</p>

<p>Surmodics, Inc. (NASDAQ:SRDX - Get Free Report)'s stock price traded up 8.7% on Monday following a better than expected earnings announcement. The company traded as high as $38.33 and last traded at $38.48. 194,800 shares were traded during trading, an increase of 10% from the average session volume of 176,503 shares. The stock had previously closed at $35.41.</p>
<div class="lb-trans"><p>Surmodics, Inc.（纳斯达克代码：SRDX - 获取免费报告）周一股价上涨了 8.7%，因其发布的财报超出预期。该公司股价最高达到 38.33 美元，最后交易价为 38.48 美元。在交易过程中，共成交 194,800 股，较 176,503 股的平均交易量增加了 10%。该股票此前收盘价为 35.41 美元。</p>
</div><p>The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.27. Surmodics had a negative net margin of 14.59% and a negative return on equity of 3.04%. The firm had revenue of $29.57 million for the quarter, compared to the consensus estimate of $28.04 million.</p>
<div class="lb-trans"><p>该公司报告本季度每股收益为 0.06 美元，超出市场共识预期的-0.21 美元，超出幅度为 0.27 美元。Surmodics 的净利润率为-14.59%，股本回报率为-3.04%。该公司本季度的收入为 2957 万美元，而市场共识预期为 2804 万美元。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>A number of research firms have recently issued reports on SRDX. Needham &amp; Company LLC reiterated a &#34;hold&#34; rating on shares of Surmodics in a report on Wednesday, April 30th. Barrington Research reiterated a &#34;market perform&#34; rating on shares of Surmodics in a report on Monday.</p>
<div class="lb-trans"><p>多家研究机构最近对 SRDX 发布了报告。Needham &amp; Company LLC 在 4 月 30 日的报告中重申了对 Surmodics 股票的 “持有” 评级。Barrington Research 在周一的报告中重申了对 Surmodics 股票的 “市场表现” 评级。</p>
</div><p><strong>Get Our Latest Report on SRDX</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 SRDX 的最新报告</strong></p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A number of institutional investors and hedge funds have recently made changes to their positions in SRDX. Strs Ohio bought a new stake in shares of Surmodics in the 1st quarter worth $122,000. Legal &amp; General Group Plc increased its holdings in shares of Surmodics by 34.2% in the 4th quarter. Legal &amp; General Group Plc now owns 3,452 shares of the company's stock worth $137,000 after purchasing an additional 880 shares in the last quarter. Price T Rowe Associates Inc. MD bought a new stake in shares of Surmodics in the 4th quarter worth $217,000. AlphaQuest LLC bought a new stake in shares of Surmodics in the 1st quarter worth $232,000. Finally, DeepCurrents Investment Group LLC bought a new stake in shares of Surmodics in the 4th quarter worth $260,000. Hedge funds and other institutional investors own 96.63% of the company's stock.</p>
<div class="lb-trans"><p>多家机构投资者和对冲基金最近对 SRDX 的持仓进行了调整。Strs Ohio 在第一季度购买了 Surmodics 的新股份，价值 12.2 万美元。Legal &amp; General Group Plc 在第四季度将其在 Surmodics 的持股增加了 34.2%。Legal &amp; General Group Plc 目前拥有 3452 股该公司的股票，价值 13.7 万美元，此前在上个季度又购买了 880 股。Price T Rowe Associates Inc. MD 在第四季度购买了 Surmodics 的新股份，价值 21.7 万美元。AlphaQuest LLC 在第一季度购买了 Surmodics 的新股份，价值 23.2 万美元。最后，DeepCurrents Investment Group LLC 在第四季度购买了 Surmodics 的新股份，价值 26 万美元。对冲基金和其他机构投资者持有该公司 96.63% 的股份。</p>
</div><h2>Surmodics Stock Up 8.2%</h2>
<div class="lb-trans"><h2>Surmodics 股价上涨 8.2%</h2>
</div><p>The company has a market cap of $547.78 million, a P/E ratio of -31.04 and a beta of 1.31. The company has a quick ratio of 3.10, a current ratio of 3.91 and a debt-to-equity ratio of 0.27. The company has a fifty day moving average of $31.27 and a 200 day moving average of $30.78.</p>
<div class="lb-trans"><p>该公司的市值为 5.4778 亿美元，市盈率为-31.04，贝塔值为 1.31。该公司的速动比率为 3.10，流动比率为 3.91，债务与股本比率为 0.27。该公司的 50 日移动平均线为 31.27 美元，200 日移动平均线为 30.78 美元。</p>
</div><h2>About Surmodics</h2>
<div class="lb-trans"><h2>关于 Surmodics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).</p>
<div class="lb-trans"><p>Surmodics, Inc 及其子公司在美国及国际上提供用于血管内医疗设备的性能涂层技术，以及用于体外诊断免疫测定测试和微阵列的化学和生物成分。它通过医疗设备和体外诊断（IVD）两个部门运营。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>阅读更多</h2>
</div><ul>
<li>Five stocks we like better than Surmodics</li>
<li>Profitably Trade Stocks at 52-Week Highs</li>
<li>Oracle’s 2025 Rally Is Only Half Over: 5 Reasons Why</li>
<li>Why Special Dividends Can be a Delightful Surprise for Income Investors</li>
<li>Invest in AI and Energy Infrastructure With These 5 ETFs</li>
<li>Uptrend Stocks Explained: Learn How to Trade Using Uptrends</li>
<li>3 Natural Gas Stocks Powering the AI Data Center Boom</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Surmodics 更好</li>
<li>在 52 周高点盈利交易股票</li>
<li>甲骨文 2025 年的反弹仅完成一半：五个原因</li>
<li>为什么特别股息对收入投资者来说可能是一个愉快的惊喜</li>
<li>通过这五只 ETF 投资人工智能和能源基础设施</li>
<li>上升趋势股票解析：学习如何利用上升趋势进行交易</li>
<li>三只推动人工智能数据中心繁荣的天然气股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Surmodics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Surmodics 吗？</h2>
</div><p>Before you consider Surmodics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Surmodics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Surmodics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄推荐给客户的股票，以便在更广泛的市场注意到之前购买……而 Surmodics 并不在名单上。</p>
</div><p>While Surmodics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Surmodics 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Surmodics（纳斯达克代码：SRDX）因盈利表现超出预期，股价上涨 8.7%